ストックスクリーナーアプリを入手
38.74
0.57%
0.22
前日終値:
$38.52
開ける：
$38.81
24時間の取引高:
3.22M
Relative Volume:
0.70
時価総額：
$78.35B
収益：
$40.10B
当期純損益:
$3.26B
株価収益率:
24.47
EPS:
1.5831
ネットキャッシュフロー:
$4.57B
1週間 パフォーマンス:
-1.27%
1か月 パフォーマンス:
+3.86%
6か月 パフォーマンス:
-4.84%
1年 パフォーマンス:
-9.63%
1日の値動き範囲:
$38.59
$38.98
1週間の範囲:
$37.76
$39.31
52週間の値動き範囲:
$31.71
$45.92
Gsk Plc Adr Stock (GSK) Company Profile
GSK を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GSK
Gsk Plc Adr
|
38.74 | 78.35B | 40.10B | 3.26B | 4.57B | 1.5831 |
|
LLY
Lilly Eli Co
|
822.51 | 738.75B | 45.04B | 10.59B | 414.30M | 11.71 |
|
ABBV
Abbvie Inc
|
205.29 | 363.15B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
163.71 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
NVO
Novo Nordisk Adr
|
69.30 | 311.44B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
MRK
Merck Co Inc
|
89.23 | 225.40B | 64.17B | 17.12B | 18.10B | 6.73 |
Gsk Plc Adr Stock (GSK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-12 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-11-15 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2024-11-12 | ダウングレード | Jefferies | Buy → Hold |
| 2024-10-31 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-07-08 | ダウングレード | UBS | Buy → Neutral |
| 2024-05-30 | 開始されました | Goldman | Neutral |
| 2024-03-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2024-02-13 | アップグレード | Citigroup | Neutral → Buy |
| 2024-01-23 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-01-16 | 再開されました | UBS | Buy |
| 2024-01-03 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Reduce |
| 2023-03-17 | アップグレード | Deutsche Bank | Hold → Buy |
| 2023-02-27 | 再開されました | Goldman | Buy |
| 2023-01-03 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-12-05 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-11-11 | ダウングレード | UBS | Neutral → Sell |
| 2022-09-15 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2022-09-08 | ダウングレード | Jefferies | Buy → Hold |
| 2022-08-05 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-07-21 | 再開されました | Citigroup | Neutral |
| 2022-02-11 | ダウングレード | DZ Bank | Buy → Hold |
| 2021-11-05 | アップグレード | Barclays | Underweight → Equal Weight |
| 2021-06-24 | アップグレード | Deutsche Bank | Sell → Hold |
| 2021-03-23 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-04 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2021-01-20 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2021-01-15 | 開始されました | Deutsche Bank | Hold |
| 2020-11-02 | アップグレード | Liberum | Hold → Buy |
| 2020-09-29 | 開始されました | Berenberg | Buy |
| 2020-02-12 | ダウングレード | Shore Capital | Hold → Sell |
| 2020-01-16 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2019-12-02 | 開始されました | SVB Leerink | Outperform |
| 2019-11-21 | アップグレード | UBS | Neutral → Buy |
| 2019-10-11 | アップグレード | Cantor Fitzgerald | Hold → Buy |
| 2019-09-03 | 再開されました | Citigroup | Neutral |
| 2019-09-03 | アップグレード | Societe Generale | Sell → Buy |
| 2019-08-13 | 再開されました | JP Morgan | Neutral |
| 2019-06-17 | 再開されました | Morgan Stanley | Underweight |
| 2019-03-08 | ダウングレード | Shore Capital | Buy → Hold |
| 2019-02-22 | ダウングレード | UBS | Buy → Neutral |
| 2019-01-14 | ダウングレード | Exane BNP Paribas | Outperform → Neutral |
| 2018-12-11 | 再開されました | Jefferies | Buy |
| 2018-10-09 | 開始されました | Guggenheim | Neutral |
| 2018-08-30 | ダウングレード | Liberum | Buy → Hold |
| 2018-04-04 | アップグレード | Exane BNP Paribas | Neutral → Outperform |
| 2018-03-22 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2018-02-09 | アップグレード | Kepler | Reduce → Hold |
すべてを表示
Gsk Plc Adr (GSK) 最新ニュース
Is GSK plc (GSK) the Best ADR Stock to Buy According to Hedge Funds? - Insider Monkey
Deadline Alert: GSK plc. (GSK) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - TradingView
GSK's Vaccine and HIV Portfolios Support Ongoing Innovation in Oncology and Immunology - Morningstar
GSK Secures FDA Nod for Oral Antibiotic to Treat Urinary Tract Infection - Yahoo Finance
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of GSK - GlobeNewswire Inc.
Deadline Alert: GSK plc. (GSK) Investors Who Lost Money - GlobeNewswire
How Do Things Look For GSK Plc ADR (NYSE: GSK) In The Short-Term? - Stocks Register
GSK Lead Plaintiff Deadline Approaching – Contact Robbins - GlobeNewswire
GSK Lead Plaintiff Deadline Approaching – Contact Robbins LLP for Information About How to Lead the GSK PLC Class Action - TradingView
Why GSK (GSK) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Bioengineered Protein Drugs Market Size to Cross USD 672.7 Billion by 2034, Growing at a CAGR of 6.2% - GlobeNewswire Inc.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Finance
GILD Data on Once-Yearly Lenacapavir for HIV Prevention Positive - Zacks Investment Research
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GSK plc of Class Action Lawsuit and Upcoming DeadlinesGSK - PR Newswire
IONS/AZN Get FDA Nod for Amyloidosis Drug, Wainzua in Europe - Zacks Investment Research
The Best Defensive Stocks to Buy Now - Morningstar
Biotech Stocks Roundup: CMRX Up on JAZZ Bid, MRNA Up on Updates & More - Yahoo Finance
The Best Women-Led Companies to Own: 2025 Edition - Morningstar
GSK’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
Why weight-loss drugs are the top target of Medicare price negotiations - Equities News
GSK Securities Class Action: GSK PLC Investors Should Contact Robbins LLP for Information About the Lead Plaintiff Deadline in the GSK Class Action Lawsuit - The Malaysian Reserve
5 Undervalued Stocks That Crushed Q4 Earnings - Morningstar
Shareholder Rights Law Firm Robbins LLP Reminds GSK Investors with Large Losses to Seek Advice on Leading the GSK PLC Class Action - PR Newswire
A closer look at Gold Fields Ltd ADR’s (GFI) current quarter earnings projections - US Post News
Law Offices of Frank R. Cruz Encourages GSK plc. (GSK) Investors To Inquire About Securities Fraud Class Action - Business Wire
Deadline Approaching: GSK plc. (GSK) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith - Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages GSK plc. (GSK) Investors To Inquire About Securities Fraud Class Action - Business Wire
Is GSK Plc ADR (GSK) worth investing in despite its undervalued state? - US Post News
Chewy Inc (CHWY) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News
Law Offices of Howard G. Smith Encourages GSK plc. (GSK) Investors To Inquire About Securities Fraud Class Action - Business Wire
GSK PLC Stockholder Notice: Shareholder Rights Law Firm - GlobeNewswire
Gsk Plc Adr (GSK) 財務データ
収益
当期純利益
現金流量
EPS
1.66%
大文字化:
|
ボリューム (24 時間):